In vivo Imaging of Biological Tissues with Combined Two-Photon Fluorescence and Stimulated Raman Scattering Microscopy

Executive Industry Relevance

Dual-modal two-photon fluorescence and stimulated Raman scattering (TPEF-SRS) microscopy enables high-resolution, label-free imaging of live biological tissues, providing critical biochemical and biophysical insights. This capability supports mechanistic de-risking and predictive confidence in early discovery and preclinical research, particularly for neurodegenerative disease and injury models. Integrating these imaging modalities advances portfolio decision-making by clarifying dynamic cellular processes in disease-relevant systems.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Enables direct visualization of cellular metabolism and immune response in native tissue environments.
• Supports functional target validation by revealing subcellular structures and interactions in vivo.
• Facilitates mechanistic de-risking through real-time observation of tissue remodeling and disease progression.
• Improves predictive confidence for target engagement and pathway interrogation in neurological models.

Screening & Assay Development

• Provides validated, quantitative imaging outputs for downstream assay development.
• Supports reproducibility and standardization by leveraging intrinsic molecular contrast without exogenous labels.
• Enables preparation of disease-relevant biological systems for compound evaluation and screening readiness.
• Allows for scalable imaging workflows adaptable to multiple tissue types and experimental conditions.

Translational & Preclinical Research

• Aligns imaging outputs with translational biomarkers relevant to neurodegenerative disease and injury models.
• Ensures continuity from discovery through preclinical validation by enabling in vivo monitoring of disease processes.
• Supports risk-adjusted advancement decisions by providing functional and structural data in live animal models.
• Enhances predictive de-risking for therapeutic hypotheses in central nervous system research.

Pipeline & Workflow Integration

This dual-modal imaging method bridges early discovery, target validation, and preclinical research by enabling real-time, quantitative analysis of live tissue dynamics.

• Discovery Biology: Supports hypothesis testing and pathway clarification through direct observation of cellular and subcellular events.
• Screening: Delivers reproducible, quantitative imaging outputs suitable for assay development and compound screening.
• Analytics: Provides high-content, label-free readouts for comparative analysis of experimental conditions.
• Translational Research: Connects imaging data to disease-relevant biomarkers and preclinical endpoints in neurological models.
• Enterprise Reuse: Establishes a reusable imaging platform adaptable across multiple research programs and tissue systems.

Operational & Enterprise Impact

• Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in disease modeling.
• Operational Value: Standardizes imaging workflows and enhances reproducibility across studies.
• Strategic Value: Informs go/no-go decisions and improves capital efficiency by clarifying biological risk early.
• Portfolio Impact: Enables risk-adjusted prioritization and advancement of neurological and tissue remodeling programs.

Implementation Considerations

• Requires expertise in advanced optical imaging and laser alignment.
• Demands specialized instrumentation, including synchronized lasers and high-speed detectors.
• Necessitates cross-team standardization of imaging parameters and data analysis workflows.
• Adaptation across tissue types may require protocol optimization for sample preparation and stabilization.
• Motion artifacts and imaging depth limitations must be managed for consistent in vivo results.

Biopharma FAQs